Composite renal endpoints: was ACCOMPLISH accomplished?
- 1 April 2010
- journal article
- editorial
- Published by Elsevier BV in The Lancet
- Vol. 375 (9721), 1140-1142
- https://doi.org/10.1016/s0140-6736(10)60098-0
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trialThe Lancet, 2010
- Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk PatientsNew England Journal of Medicine, 2008
- Effects of Dietary Sodium and Hydrochlorothiazide on the Antiproteinuric Efficacy of LosartanJournal of the American Society of Nephrology, 2008
- Direct comparison of the effects of valsartan and amlodipine on renal hemodynamics in human essential hypertension.American Journal of Hypertension, 2003
- The effects of an ACE inhibitor and a calcium antagonist on the progression of renal disease: the Nephros StudyNephrology Dialysis Transplantation, 2001
- The Effect of Irbesartan on the Development of Diabetic Nephropathy in Patients with Type 2 DiabetesNew England Journal of Medicine, 2001
- Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and NephropathyNew England Journal of Medicine, 2001
- Angiotensin-Converting Enzyme Inhibitor–Associated Elevations in Serum CreatinineArchives of Internal Medicine, 2000
- The Effects of Dietary Protein Restriction and Blood-Pressure Control on the Progression of Chronic Renal DiseaseNew England Journal of Medicine, 1994